India Pharma Outlook Team | Wednesday, 09 September 2026
Tylenol exposure in pregnancy draws scrutiny as the latest evidence shows possible links to changes in daughters’ reproductive organs.
Researchers track acetaminophen use and find smaller ovaries and uteruses in infant girls. The study examines urine samples from mothers and measures organ size plus hormone levels in three-month-old babies.
Early exposure before 17 weeks of pregnancy stands out with lower Anti-Mullerian hormone readings. Scientists stress that the work stops short of proving cause and effect and offers no clear signal on future fertility.
Current guidelines still list Tylenol as a safe choice for pain and fever relief during pregnancy because untreated high fever or severe pain carries its own risks for mother and fetus.
A woman’s reproductive capacity takes shape in the womb, and girls arrive with their full lifetime egg supply already set. The Copenhagen team led by Margit Bistrup Fischer reports that infants exposed in utero carry smaller ovaries with fewer follicles that hold immature eggs.
They also record smaller uteruses and reduced levels of key reproductive hormones. These differences appear even though the mothers use modest amounts of the drug. The researchers note that animal studies had already pointed toward possible effects on ovarian reserve, yet this marks the first human data of its kind.
Also Read: How Regulatory Readiness Can Shape Pharma's Global Growth
Fischer states that women who used Tylenol during pregnancy need not feel alarmed. Many daughters of users display ovarian measurements similar to those of unexposed infants. The study cannot predict outcomes for any single child, and it does not prove the medicine causes the observed changes.
Long-term follow-up must track the girls into adulthood to learn whether the size differences affect fertility or the timing of menopause. Dr. Christian De Geyter, writing in an accompanying commentary, observes that the human findings align with earlier animal research. He recommends extending observation through menopause and suggests that pregnancy guidelines for the drug may need another look.
Guidelines continue to endorse Tylenol for treating pain and fever in pregnancy. Fischer points out that leaving high fever or intense pain untreated can itself harm the mother and the developing fetus. The latest evidence therefore adds a new layer of detail rather than an immediate change in advice.
It invites deeper investigation into how common medications interact with the delicate process of building female reproductive organs. Researchers and clinicians now face the task of following these cohorts further so that future recommendations rest on clearer long-term data.
